Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 7/20 | 0.42 |
| ▸ | BACE1 | P56817 | 5/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2266932 | 1.00 | CYP2C9 (0.56) | CYP2C9CYP3A4CYP2D6KCNH2CYP2C19 | |
| SCHEMBL2260140 | 0.89 | KCNH2 (0.53) | CYP2C9CYP3A4CYP2D6KCNH2CYP2C19 | |
| SCHEMBL2266003 | 0.87 | CYP3A4 (0.55) | CYP2C9CYP3A4CYP2D6KCNH2CYP2C19 | |
| SCHEMBL2265996 | 0.87 | CYP3A4 (0.55) | CYP2C9CYP3A4CYP2D6KCNH2CYP2C19 | |
| SCHEMBL2265606 | 0.84 | CYP3A4 (0.46) | CYP2C9CYP3A4CYP2D6KCNH2CYP2C19 | |
| SCHEMBL2265610 | 0.84 | CYP3A4 (0.46) | CYP2C9CYP3A4CYP2D6KCNH2CYP2C19 | |
| SCHEMBL2260788 | 0.83 | CYP3A4 (0.49) | CYP2C9CYP3A4CYP2D6KCNH2CYP2C19 | |
| SCHEMBL2260782 | 0.83 | CYP3A4 (0.49) | CYP2C9CYP3A4CYP2D6KCNH2CYP2C19 | |
| SCHEMBL2262084 | 0.82 | ACHE (0.47) | CYP2C9KCNH2CYP2C19ACHEBACE1 | |
| SCHEMBL2260848 | 0.79 | KCNH2 (0.45) | CYP2C9KCNH2CYP2C19ACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089384-B1 | 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | claimed |
| US-7998969-B2 | enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases | ROCHE PALO ALTO LLC (US) | 2011-08-16 | — | — | US | claimed |
| EP-2089384-A2 | 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-08-19 | — | — | EP | claimed |
| US-20080146595-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | claimed |
| WO-2008071587-A2 | 2-(PIPERIDIN-4-YL)-4-PHENOXY- OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146595-A1 | Non-nucleoside reverse transcriptase inhibitors | NQO2, SAMHD1, POLR2A | CYP2C9 1382/4885CYP3A4 832/4885CYP2D6 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.